Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 17.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 274,134 shares of the medical equipment provider's stock after acquiring an additional 40,866 shares during the quarter. Deutsche Bank AG owned approximately 0.39% of Lantheus worth $24,524,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. raised its holdings in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Lantheus during the fourth quarter worth about $36,183,000. Swedbank AB lifted its position in shares of Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Keybank National Association OH acquired a new stake in shares of Lantheus during the fourth quarter worth about $27,526,000. Finally, Norges Bank acquired a new stake in shares of Lantheus during the fourth quarter worth about $26,189,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research reports. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Truist Financial reduced their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $132.67.

Insider Buying and Selling

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company's stock.

Lantheus Price Performance

Shares of LNTH stock traded up $1.46 during trading hours on Friday, reaching $81.24. 913,883 shares of the stock were exchanged, compared to its average volume of 981,515. The business's fifty day moving average is $97.11 and its two-hundred day moving average is $93.20. Lantheus Holdings, Inc. has a 12-month low of $75.00 and a 12-month high of $126.89. The firm has a market capitalization of $5.62 billion, a P/E ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the previous year, the company posted $1.69 earnings per share. The firm's quarterly revenue was up .8% on a year-over-year basis. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.